Dimensional Fund Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Dimensional Fund Advisors LP increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 14.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 947,301 shares of the company's stock after acquiring an additional 122,695 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.11% of CRISPR Therapeutics worth $37,283,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $39,000. Western Pacific Wealth Management LP lifted its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics during the third quarter valued at about $40,000. Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $80,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

Analysts Set New Price Targets

CRSP has been the topic of a number of analyst reports. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Needham & Company LLC dropped their target price on shares of CRISPR Therapeutics from $84.00 to $81.00 and set a "buy" rating for the company in a report on Wednesday. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target for the company in a report on Wednesday, February 12th. Finally, Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $71.58.

Insider Activity at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last quarter. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded down $0.48 during midday trading on Friday, reaching $35.66. The company's stock had a trading volume of 1,485,447 shares, compared to its average volume of 2,178,506. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The company has a market cap of $3.08 billion, a P/E ratio of -8.16 and a beta of 1.88. The business's 50 day moving average price is $38.31 and its two-hundred day moving average price is $42.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The business's revenue was up 71.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.43) EPS. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.